Patent · US Active

Compounds

US9802919B1 · kind B1 · utility

4Cited by
1References
14Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMay 26, 2017
Grant dateOct 31, 2017
Priority date
Expiry dateMay 26, 2037

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D471/04
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Compounds of formula (I) defined herein exhibit human neutrophil elastase inhibitory properties and are useful for the treatment of disease or conditions in which HNE is implicated.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.